AlphAIAlphAI — Financial news for AI agents
investing.comOCT 82 min read$BHVN

Raymond James reiterates Strong Buy on Biohaven stock after Japan deal

Raymond James maintained a Strong Buy rating and $30.00 price target for Biohaven Pharma (BHVN) after its licensing deal with Ono Pharma. The deal brings Biohaven $100 million in cash, extending its cash runway into 2029. The stock trades at $11.66, with a market cap of $1.79 billion. Biohaven also faces a partial clinical hold on its BHV-7000 epilepsy program. Baird reiterated an Outperform rating, while RBC downgraded to Sector Perform with a $19.00 target.

Original reporting
investing.com
Published Oct 8, 2026, 2:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 2:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$BHVN
Bullish
high confidence
Mentioned
$BHVN
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$BHVNBullishMed
01

Why it matters

The analyst upgrade and cash infusion are fresh, material information that can move the stock in the short term.

02

Market read

The licensing deal and analyst upgrade provide a clear catalyst for Biohaven, likely prompting short‑term buying interest.

03

What to watch

Potential regulatory hurdles for BHV‑1300 and the company's existing cash burn could limit upside.

Relevance 7/10Novelty 7/10Timing: immediate

Background

Biohaven Pharma (NYSE:BHVN) is a neuro‑pharma company developing BHV‑1300 for Graves’ disease. The licensing agreement with Japan’s Ono Pharma adds $100 M cash and rights to commercialize the drug in Japan.

Company-level read

Ticker impact

$BHVNBullishHigh confidence
Context

Raymond James reiterated a Strong Buy rating and set a $30 price target after Biohaven announced a $100 million licensing deal with Ono Pharma, providing near‑term cash and extending its runway.

Expected impact

upward pressure as the market prices in the new cash and longer runway

Evidence & confidence

Analyst upgrade with a concrete $30 target and $100 M cash boost constitute fresh, material news.

Market effects

Sector

Strengthens the biotech licensing sector by showing viable cash‑flow partnerships.

Regional

Positive for U.S. biotech stocks as a high‑profile licensing deal is announced.

Global

Highlights cross‑border pharma collaborations, modestly supportive for global biotech sentiment.

Counterpoint

What could challenge this read

The deal may not translate into long‑term profitability if BHV‑1300 fails in later trials.

Key entities

  • company
    Biohaven Pharma

    US‑listed biotech firm receiving licensing deal.

  • company
    Ono Pharma

    Japanese partner acquiring rights to BHV‑1300.

  • analyst
    Raymond James

    Equity research firm reiterating Strong Buy and $30 target.

Read at source← All news

Related articles

OCT 8
$BHVNMed

Ono Pharma inks license agreement with Biohaven

Ono Pharmaceutical (TYO: 4528) has signed an exclusive license deal with Biohaven (NYSE: BHVN) for Biohaven's IgG degrader portfolio, including BHV-1300, in Japan, South Korea, Taiwan, and ASEAN. The portfolio targets autoimmune diseases by degrading disease-causing autoantibodies. BHV-1300 is in global Phase III trials for Graves' disease, according to the companies.

thepharmaletter.com2 min
OCT 8
$BHVNMed

Biohaven Licenses IgG Degrader Portfolio To Ono Pharma In Key Asian Markets

Biohaven (BHVN) has licensed its IgG degrader portfolio to Ono Pharma for Asian markets, including Japan and South Korea. The deal includes up to $100M in payments, with Biohaven retaining rights outside these regions. The portfolio, led by BHV-1300 in Phase 3 trials for Graves' disease, aims to treat autoimmune disorders. Biohaven's stock closed at $11.88, up 1.18% in pre-market trading.

rttnews.com2 min
OCT 8
HighAI 8/10

Ono Pharmaceutical: Pharma Announces an Exclusive License Agreement with Biohaven to Develop and Commercialize IgG Degraders in Japan, South Korea, Taiwan, and ASEAN Countries

Ono Pharmaceutical has secured exclusive rights from Biohaven to develop and commercialize IgG degrader therapeutics, including BHV-1300, in Japan, South Korea, Taiwan, and ASEAN countries. Ono will pay $80M upfront, $20M in milestones, and 20% royalties. BHV-1300 is in global Phase 3 trials for Graves' disease.

marketscreener.com2 min
OCT 8
$BHVNMed

Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease

Biohaven (BHVN) has entered a licensing agreement with Ono Pharma for its extracellular IgG degraders in Japan and select Asian regions. Biohaven will receive up to $100 million in payments, including $80 million upfront, and 20% royalties on net sales. The lead candidate, BHV-1300, is in Phase 3 trials for Graves' disease. Biohaven retains rights to the portfolio outside the licensed territory.

prnewswire.com2 min